CL2022003622A1 - Molécula de unión al antígeno anti-células t para usarse con un inhibidor de angiogénesis - Google Patents
Molécula de unión al antígeno anti-células t para usarse con un inhibidor de angiogénesisInfo
- Publication number
- CL2022003622A1 CL2022003622A1 CL2022003622A CL2022003622A CL2022003622A1 CL 2022003622 A1 CL2022003622 A1 CL 2022003622A1 CL 2022003622 A CL2022003622 A CL 2022003622A CL 2022003622 A CL2022003622 A CL 2022003622A CL 2022003622 A1 CL2022003622 A1 CL 2022003622A1
- Authority
- CL
- Chile
- Prior art keywords
- cell antigen
- antigen binding
- cells
- cytokine release
- binding molecule
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title abstract 4
- 102000036639 antigens Human genes 0.000 title abstract 4
- 108091007433 antigens Proteins 0.000 title abstract 4
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 title 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 title 1
- 239000004037 angiogenesis inhibitor Substances 0.000 title 1
- 210000004027 cell Anatomy 0.000 abstract 4
- 102000004127 Cytokines Human genes 0.000 abstract 3
- 108090000695 Cytokines Proteins 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 3
- 230000009885 systemic effect Effects 0.000 abstract 3
- 230000016396 cytokine production Effects 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 239000002525 vasculotropin inhibitor Substances 0.000 abstract 2
- 230000004075 alteration Effects 0.000 abstract 1
- 238000002648 combination therapy Methods 0.000 abstract 1
- 239000012636 effector Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008177 pharmaceutical agent Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/99—Enzyme inactivation by chemical treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
Abstract
La presente invención se refiere a métodos para prevención, alivio o tratamiento de liberación de citocina resultando de la administración de un inhibidor VEGF o efectos secundarios resultando de la liberación de citocina. Para prevenir, aliviar o tratar liberación de citocina o sus efectos secundarios, la descripción también proporciona terapias de combinación que usan un agente farmacéutico que estimula el linfocito, representado por una molécula de unión al antígeno de anti-célula T, con un inhibidor VEGF. Entre las moléculas de unión al antígeno anti-célula T, por ejemplo, anticuerpos que reclutan células T como células efectoras en tejidos de tumor son llamadas células T redireccionando anticuerpos, y se conocen como medios para tratar tumores. Por otra parte, cuando la producción de citocina sistémica es estimulada por unión de anticuerpos a células T, se teme que esta acción sistémica pueda conducir a aberraciones tal como CRS. La presente descripción proporciona medios para aliviar la producción de citocina sistémica, y puede permitir usar de forma más segura las moléculas de unión al antígeno anti-célula T en el tratamiento de tumor.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020106501 | 2020-06-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2022003622A1 true CL2022003622A1 (es) | 2023-06-23 |
Family
ID=79268097
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2022003622A CL2022003622A1 (es) | 2020-06-19 | 2022-12-16 | Molécula de unión al antígeno anti-células t para usarse con un inhibidor de angiogénesis |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20230235056A1 (es) |
| EP (1) | EP4186527A1 (es) |
| JP (2) | JP7250219B2 (es) |
| KR (2) | KR20230152789A (es) |
| CN (1) | CN115768478A (es) |
| AU (1) | AU2021292932A1 (es) |
| BR (1) | BR112022025536A2 (es) |
| CA (1) | CA3180951A1 (es) |
| CL (1) | CL2022003622A1 (es) |
| CR (1) | CR20230014A (es) |
| IL (1) | IL299127A (es) |
| MX (1) | MX2022015764A (es) |
| PE (1) | PE20230435A1 (es) |
| TW (1) | TW202214286A (es) |
| WO (1) | WO2021256555A1 (es) |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773719A (en) | 1966-12-06 | 1973-11-20 | Hoffmann La Roche | 2-aminoxy-2'-acyl-acetanilide |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| ATE375365T1 (de) | 1998-04-02 | 2007-10-15 | Genentech Inc | Antikörper varianten und fragmente davon |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| HUP0104865A3 (en) | 1999-01-15 | 2004-07-28 | Genentech Inc | Polypeptide variants with altered effector function |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| ES2528794T3 (es) | 2000-04-11 | 2015-02-12 | Genentech, Inc. | Anticuerpos multivalentes y usos de los mismos |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| DE60332957D1 (de) | 2002-12-16 | 2010-07-22 | Genentech Inc | Immunoglobulinvarianten und deren verwendungen |
| EP2471816A1 (en) | 2006-08-30 | 2012-07-04 | Genentech, Inc. | Multispecific antibodies |
| US8337854B2 (en) | 2007-04-04 | 2012-12-25 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Monoclonal antibodies against dengue and other viruses with deletion in Fc region |
| PT2235064E (pt) | 2008-01-07 | 2016-03-01 | Amgen Inc | Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática |
| AR084053A1 (es) | 2010-11-30 | 2013-04-17 | Chugai Pharmaceutical Co Ltd | Agente terapeutico que induce citotoxicidad |
| ES2900898T3 (es) | 2014-04-07 | 2022-03-18 | Chugai Pharmaceutical Co Ltd | Anticuerpos biespecíficos inmunoactivadores |
| MA40764A (fr) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
| TW202342540A (zh) * | 2016-03-14 | 2023-11-01 | 日商中外製藥股份有限公司 | 用於癌之治療的細胞傷害誘導治療劑 |
| JP7125347B2 (ja) | 2016-08-22 | 2022-08-24 | 中外製薬株式会社 | ヒトｇｐｃ３ポリペプチドを発現する遺伝子改変非ヒト動物 |
| AU2017361081A1 (en) * | 2016-11-15 | 2019-05-23 | Genentech, Inc. | Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodies |
| AU2018243571B2 (en) * | 2017-03-31 | 2024-03-07 | The Board Of Trustees Of The Leland Standford Junior University | Methods of treating T cell exhaustion by inhibiting or modulating T cell receptor signaling |
-
2021
- 2021-06-18 CR CR20230014A patent/CR20230014A/es unknown
- 2021-06-18 JP JP2022531930A patent/JP7250219B2/ja active Active
- 2021-06-18 IL IL299127A patent/IL299127A/en unknown
- 2021-06-18 PE PE2022002932A patent/PE20230435A1/es unknown
- 2021-06-18 CN CN202180043015.4A patent/CN115768478A/zh active Pending
- 2021-06-18 TW TW110122300A patent/TW202214286A/zh unknown
- 2021-06-18 BR BR112022025536A patent/BR112022025536A2/pt unknown
- 2021-06-18 AU AU2021292932A patent/AU2021292932A1/en active Pending
- 2021-06-18 KR KR1020237036198A patent/KR20230152789A/ko active Application Filing
- 2021-06-18 CA CA3180951A patent/CA3180951A1/en active Pending
- 2021-06-18 EP EP21825999.2A patent/EP4186527A1/en active Pending
- 2021-06-18 WO PCT/JP2021/023149 patent/WO2021256555A1/ja active Application Filing
- 2021-06-18 KR KR1020227039674A patent/KR102594943B1/ko active IP Right Grant
- 2021-06-18 US US18/010,615 patent/US20230235056A1/en active Pending
- 2021-06-18 MX MX2022015764A patent/MX2022015764A/es unknown
-
2022
- 2022-12-16 CL CL2022003622A patent/CL2022003622A1/es unknown
-
2023
- 2023-03-20 JP JP2023043678A patent/JP2023078311A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR102594943B1 (ko) | 2023-10-27 |
| US20230235056A1 (en) | 2023-07-27 |
| CN115768478A (zh) | 2023-03-07 |
| KR20230028225A (ko) | 2023-02-28 |
| JP7250219B2 (ja) | 2023-03-31 |
| KR20230152789A (ko) | 2023-11-03 |
| JP2023078311A (ja) | 2023-06-06 |
| PE20230435A1 (es) | 2023-03-08 |
| IL299127A (en) | 2023-02-01 |
| EP4186527A1 (en) | 2023-05-31 |
| CA3180951A1 (en) | 2021-12-23 |
| WO2021256555A1 (ja) | 2021-12-23 |
| MX2022015764A (es) | 2023-01-19 |
| JPWO2021256555A1 (es) | 2021-12-23 |
| AU2021292932A1 (en) | 2023-01-05 |
| CR20230014A (es) | 2023-02-17 |
| BR112022025536A2 (pt) | 2023-01-17 |
| TW202214286A (zh) | 2022-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2020002945A1 (es) | Métodos para tratar cánceres y potenciar la eficacia de agentes terapéuticos para el redireccionamiento de células t | |
| MX2018014950A (es) | Terapia de combinacion. | |
| CL2023000846A1 (es) | Terapia de combinación que incluye inhibidor de krasg12c y agente farmacéuticamente activo para tratar cáncer | |
| WO2018026819A3 (en) | Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule | |
| BR112018076306A2 (pt) | composições e métodos para a supressão de células cd117+ | |
| WO2019099639A8 (en) | Bcma-targeting chimeric antigen receptor, cd19-targeting chimeric antigen receptor, and combination therapies | |
| BR112018070676A2 (pt) | construtos de ligação a antígeno multiespecífico que têm como alvo agentes imunoterapêuticos | |
| WO2018170338A3 (en) | High affinity mage-a1-specific tcrs and uses thereof | |
| PH12019501663A1 (en) | Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate | |
| MX2023003470A (es) | Anticuerpo anti-garp. | |
| MX2021013830A (es) | Inhibidores de ezh2 para tratar linfomas. | |
| MX2017015811A (es) | Tratamiento de cancer por bloqueo combinado de las trayectorias de señalizacion de muerte programada 1 (pd)-1 y receptor 4 de quimiocina c-x-c(cxcr4). | |
| CO2021014076A2 (es) | Anticuerpos multiespecíficos egfr x cd28 | |
| BR112018076263A2 (pt) | composições e métodos para a depleção de células | |
| PE20170140A1 (es) | Metodos para tratar el cancer con inhibidores de tigit y agentes contra el cancer | |
| PE20210375A1 (es) | Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales | |
| WO2019084057A3 (en) | Compositions and methods for the depletion of cd117+ cells | |
| BR112019022280A2 (pt) | tratamento de cânceres de her2 positivo | |
| WO2015191568A3 (en) | Combination therapies using agents that target tumor-associated stroma or tumor cells and tumor vasculature | |
| EA201892541A1 (ru) | Гуманизированные анти-il-1r3 антитела | |
| CL2022003622A1 (es) | Molécula de unión al antígeno anti-células t para usarse con un inhibidor de angiogénesis | |
| WO2021087368A3 (en) | Anti-cd45 antibodies and conjugates thereof | |
| EA201991870A1 (ru) | Лечение рака мочевого пузыря с помощью антитела к pd-l1 | |
| MX2020011377A (es) | Metodos y composiciones para el tratamiento de urticaria cronica. | |
| MX2022015475A (es) | Proteina de fusion que comprende il-12 y anticuerpo anti-fap, y uso de la misma. |